Introduction
Chronic myeloid leukemia (CML) is uniquely distinguished from the three other common myeloproliferative disorders, essential thrombocythemia (ET), polycythemia vera (PV), and idiopathic myelofibrosis (IMF), by the Philadelphia chromosome and/or by the molecular rearrangement yielding the chimeric BCR-ABL oncogene. 1, 2 Thrombocytosis is often seen in CML patients, but thrombohemorrhagic complications are rarely reported. 2 Reduction in levels of the white blood cell and platelet counts in patients treated with interferon has been implemented by using HU and, less commonly, busulfan. Even in the imatinib era, HU has been routinely used when thrombocytosis has been excessive. 2 It is well known that increased platelet counts are associated with an increased risk of microvascular occlusion, [3] [4] [5] thrombosis, [6] [7] [8] [9] and bleeding. 10 In only one study in CML has anagrelide been reported to control the thrombocytosis and thrombohemorrhagic complications. 11 Of the 12 patients in this study, the median platelet count was approximately 2.0 million/ml; seven patients had thrombohemorrhagic complications. All patients responded to anagrelide. The median platelet count after treatment was 343 000/ml; thrombohemorrhagic complications disappeared or did not recur in all patients previously affected.
As part of a large phase II efficacy and safety trial of anagrelide in treating patients with elevated platelet counts in the myeloproliferative diseases, the Anagrelide Study Group studied a group of 114 patients with CML and thrombocytosis ( Figure 1) . 2, 12 The majority of the patients had been given anagrelide solely because the platelet count was elevated according to study criteria. However, within this group, we subsequently identified a subset of 38 patients who had been given HU prior to anagrelide specifically for the thrombohemorrhagic complications accompanying thrombocytosis.
This report emphasizes the rare complications associated with thrombocytosis in CML and its treatment with anagrelide, especially in patients not satisfactorily treated with HU that had been given for increased blood platelets. As in other myeloproliferative diseases, it suggests that aggressive platelet control aimed at reducing the number of excess blood platelets with anagrelide is a treatment objective for CML patients.
Materials and methods
The diagnosis of CML required the typical phenotypic clinical and hematologic picture and demonstration of the Philadelphia chromosome in the bone marrow in all cases. Molecular studies for rearrangement of the BCR-ABL oncogene and fluorescent in situ hybridization studies were not routinely performed in all patients at the time of the initiation of this study. Other criteria included a white blood cell count of X60 000/ml, granulocytic hyperplasia of the marrow, and decreased or absent leukocyte alkaline phosphatase score. Patients were 18 years or older and gave written informed consent. Children were treated as part of a compassionate-use program. Women of childbearing age had to have a negative pregnancy test. Failure of a prior therapy was not required.
The 114 patients with CML eligible to receive anagrelide were required to have a platelet count of at least 900 000/ml on two separate occasions at least 1 month apart or a count of at least 650 000/ml on two successive determinations and documentation of symptoms attributable to thrombocytosis.
Not all of the 114 patients were given routine prophylactic aspirin. Detailed coagulation studies for hypercoagulable states were not systematically performed. During the analysis of this group, we noted a number of patients who had been treated with HU specifically for platelet control because of thrombohemorrhagic symptoms or signs. In these 38 patients, the use of HU was not successful for this purpose; because of excessive thrombocytosis, anagrelide had been substituted. We therefore reviewed the data pertaining to this subgroup to determine the nature of the complications and the usefulness of anagrelide in this particular situation. In the majority of cases, HU had been given as a single agent; in the minority, it supplemented another drug used for treating the leukemia.
For the purpose of analysis, this subset of HU-resistant patients was divided into two groups ( Table 1 ). The first group (n ¼ 19) consisted of those whose thrombocytosis was considered refractory to HU, defined as one of the following three: (1) leukopenia with thrombocytosis (WBC p3000/ml; platelets X600 000/ml) after 3 months of HU therapy; or (2) a platelet count X900 000/ml despite a dose of at least 2 g of HU for at least 2 months; or (3) a platelet count X2 000 000/ml for at least 2 months of HU treatment at any dose. The second group (n ¼ 19) consisted of patients who were considered probably, but not definitely refractory to HU, defined as a platelet count median of 600 000/ml for at least 2 months with any dose of HU and documented symptoms and signs attributed to thrombocytosis. For the most part, these patients had had a temporary suspension of other antileukemic therapy before institution of HU because of the relatively impressive thrombocytosis.
The treatment program consisted of anagrelide 0.5 mg 4 times a day. Weekly adjustments were made to achieve and then maintain the platelet count at p600 000/ml and ideally between 300 000 and 400 000/ml. The average dose was 2.0-2.5 mg/day, but higher doses up to 7.2 mg/day were sometimes required. 12 A response was defined as a decrease in platelet count to p600 000/ml or 50% of the initial value before anagrelide. All values had to remain constant for at least 4 weeks. Treatment failure was defined as anything less than the aforementioned.
Time to platelet response was computed as the time from day 1 of anagrelide therapy until a response was first noted. Treatment time was determined from the first dosing date to the end of therapy or the last follow-up of patients still receiving treatment. Observations were censored at the time of the last dosing date of the patients still being treated. 12 Note that the end point was neither hematologic nor cytogenetic response of CML, but rather reduction of platelet counts and associated symptoms and signs contemporaneous with administration of anagrelide.
Results
During the phase II study, 114 patients with CML with elevated platelet counts were treated with anagrelide. For their leukemia, the patients had been previously treated with HU, interferon, busulfan, 32 P, chlorambucil, thiotepa, cytosine arabinoside, nitrogen mustard, and/or alkeran as antileukemic therapy. Overall, more than 70% of the 114 patients in chronic phase disease had received HU. As they had thrombocytosis as defined in the major study, they were given anagrelide as part of the single-arm, open-label trial, together with antileukemic therapy. We identified 38 patients who had been specifically given HU to treat thrombocytosis, prior to starting anagrelide. The use of anagrelide to treat the thrombocytosis after HU was the result of an inability to control the platelet count, an adverse event accompanying HU, or both.
The entire group of 114 CML patients, including the subgroup of 38 HU-resistant patients, had the age, sex, and race distribution typical of a CML cohort (Table 2) . For the 38 patients, the median age was 54.5 years; only one patient was African American. More than 90% were Caucasian, 53% were women. The mean baseline body weight was 70 kg (range 41-128 kg). All 38 patients were in chronic phase of varying duration; none had accelerated or blast phase phenotypes.
Of the 38 HU-resistant patients, 28 had a history of thrombosis and 10 had a history of hemorrhage (Table 3) . There was no distinct linear correlation between the platelet count and the development of thrombohemorrhagic symptoms in this relatively small sample, although the higher the platelet counts, the more frequent the complications.
In all, 27 patients (71%) of this subset met the criteria for response to anagrelide. After treatment there were 27 responders, but 11 patients remained symptomatic ( Leukopenia with thrombocytosis (platelets X600 000/ml) after 3 months of HU therapy, or 1.2
Platelet count X900 000/ml despite a dose of at least 2 g/day for at least 2 months, or 1.3
Platelet count X2 000 000/ml after at least 2 months of HU at any dose 2. Probably, but not definitely, refractory to HU: 19 Platelet count X600 000/ml for at least 2 months with any dose of HU and documented symptoms and signs attributed to thrombocytosis treatment, the mean platelet levels in responders and nonresponders were 250 0007360 400/ml (Table 4 ). In one-third of the responders, the initial platelet count was reduced by 50%. At 6-8 weeks, the median platelet count in two-thirds of the responders was less than 600 000/ml. The median time to best response on both subgroups was 7.1 weeks. The time to response and response rate were the same in the thrombotic and hemorrhagic groups. The mean daily dose of anagrelide was 2-2.5 mg/day. Response was not correlated with either early-or late-stage chronic phase disease, sex, age, race, or splenomegaly. The median platelet count prior to treatment with anagrelide was 1 237 000/ml, the mean 1 354 000/ml (rangeE600 000-6 300 000/ml). The responders maintained their counts for a median of 7 weeks and as long as 8 months; thereafter, the platelet counts in each patient were affected by change in censored status of CML to accelerated or blast phase disease (four patients), by alternative chemotherapy for CML (21 patients), marrow transplantation (eight patients), and by refusal of a physician to complete the paperwork (one patient). During the anagrelide trial, the median white blood cell count remained constant at about a value of 30 000/ml, but the median hemoglobin values fell from 12.0 to 9.5 g/dl. As previously noted, 12 the white blood cell count was not affected by anagrelide during the observation period.
The symptoms of the group of patients with thrombosis included transient ischemic attacks, myocardial infarction, erythromelalgia, deep venous thrombosis, and ischemia with or without cutaneous ulceration of the extremities. Ten patients had either transient ischemic attacks (9) or a myocardial infarction (1) . In the patient with myocardial infarction, it is not now known whether other cardiovascular risk factors existed or played a contributory role. The patient had serum cholesterol of 236 mg/dl. Lipoprotein values are not known. Transient ischemic attacks did not recur in seven of the nine patients, nor did the patient with the myocardial infarction suffer a recurrence after the platelet counts were lowered to p600 000/ml, at least during the observation period of the study. In two patients, symptoms persisted without change in platelet count. Additional dose escalation of anagrelide was not documented.
Similarly, the symptoms of the eight patients with erythromelalgia completely abated upon reduction of the platelet count (the use of low-dose aspirin was not documented).
No associated malignancies were found in the patients with deep venous thrombosis. Usual anticoagulation as well as platelet reduction was employed. Only one of four patients with ischemic ulcers had improvement with dermatologic care and anagrelide as the platelet counts were reduced towards normal. The possible contribution of HU in the pathogenesis of the ulcers was appreciated, 13 but a specific relation between ulcers, and change in platelet count and HU was not established.
Hemorrhage took the form of ecchymoses, gastrointestinal hemorrhage, or epistaxis (Table 3 ). In three of six patients, ecchymoses diminished clinically with decrease in the platelet No. of patients ¼ 38.
Anagrelide treats thrombocytosis RT Silver count. The three patients with gastrointestinal bleeding had a thorough evaluation to exclude other causes of contribution to bleeding; none was found. The bleeding was characterized by melena and stopped within 3 days. In only one of three patients was there a decrease in platelet count in temporal relation to cessation of bleeding. The patient with epistaxis had packing of the nasal passages in addition to treatment with anagrelide. In this patient, the platelet count was not affected by anagrelide and cessation of hemorrhage was attributed to local measures.
Toxicity attributed to anagrelide
Approximately two-thirds of the patients had side effects secondary to anagrelide, and three required cessation of anagrelide therapy despite reduction in dose (Table 5 ). This occurred in elderly patients with a history of cardiac disease in whom anagrelide was discontinued because of palpitations. In general, symptoms were mild or moderate in severity. These are shown in Table 5 and included gastrointestinal symptoms, headaches, dizziness, palpitations, and fluid retention. Dividing the daily dose of anagrelide into multiple small ones ameliorated side effects.
Discussion
Although more than half the patients with CML have platelet counts above 1 million/ml, reported thrombotic or hemorrhagic phenomena are infrequent. 2 Nevertheless, the fact that these events can occur in CML, as in other myeloproliferative disorders, is worthy of emphasis. Elevated blood platelet counts in CML have been demonstrated to be responsive to anagrelide. However, this is the first time that patients who have been refractory to HU have been shown to respond to anagrelide. The group of 114 CML patients was referred for anagrelide therapy because of abnormally high platelet counts; many of these patients did not have a history of thrombosis or hemorrhage. This subset of 38 patients resistant to HU with thrombohemorrhagic symptoms or signs was studied retrospectively. Thus, the true figures for the prevalence and frequency of thrombotic complications in CML still remain unknown. These 38 patients had been given HU specifically for the thrombocytosis. Some had received other antileukemic agents both for the leukemia and the thrombocytosis. In these 38 patients, HU was ineffective in controlling the thrombocytosis, not the leukemia.
Limitations to this retrospective study also include the fact that contributory factors, such as hypercholesterolemia and/or hypercoagulable states, were not studied systematically, nor was the dosing of aspirin consistent. Furthermore, anagrelide was not unequivocally successful in all patients. No difference could be appreciated in this analysis between those responding to anagrelide or not. This retrospective review did not disclose any significant difference based upon early or late stage of chronic disease, sex, WBC, or initial platelet count. No patient was treated with anagrelide in accelerated or blast phase disease. Nevertheless, despite the limitations of this study, amelioration of symptoms and signs of thrombosis or hemorrhage clearly coincided with the decrease in platelet count towards normal after anagrelide therapy was begun.
Anagrelide appeared more effective in treating the thrombotic rather than the hemorrhagic complications of thrombocytosis of CML. Studies of acquired von Willebrand's disease should be examined in future in similar situations in patients with CML with increased platelet counts and bleeding. 14 The response criteria stipulated at least 4 weeks of platelet control, and for responding patients an attempt was made to sustain counts below 600 000/ml. The median time to response of our CML patients of approximately 7 weeks was quite similar to the results of Fruchtman et al 15 and those of Tsimberidou et al. 16 The patients of Tsimberidou et al were treated with both anagrelide and imatinib mesylate. They suggested an independent mechanism of action of anagrelide on the thrombocytosis of CML. 17 Thus, anagrelide may have a unique application for treating the thrombocytosis of CML not shared by other chemotherapeutic agents. Our response rate of 71% is also consistent with the series of Fruchtman et al. 15 In a large group of patients with myeloproliferative diseases, excluding essential thrombocythemia, the total response rate of thrombocytosis to anagrelide was 75% entirely consistent with the frequency of 71% reported here. 15, 16 Moreover, the median time to response was 72 days, and the mean dose of anagrelide used was 2.15 mg/day, consistent with our observations.
Response duration was measured from achievement of response to therapeutic failure or reinstitution of drugs for treatment of the leukemia (which could affect the platelet count), whichever came first, or by other censored observations, such as marrow transplantation or by progression to accelerated or blast phase disease. For these reasons, duration of response to anagrelide was relatively short compared to studies in the other myeloproliferative diseases. 12, 13 The introduction of imatinib mesylate in the treatment of chronic phase CML has resulted in a dramatic change in therapeutic results. HU, however, may be used in the initial phase of therapy for debulking, especially in patients with significantly increased white blood cell counts. 18 As experience with imatinib develops, it will be interesting to see whether such thrombotic complications will also be noted in a larger series of reported CML cases, especially those with high platelet counts. To date, they have not. Nevertheless, combinations of imatinib with other agents are already being used, and in those patients with refractory thrombocytosis anagrelide may be of considerable importance.
For patients with thrombocytosis as a manifestation of CML with symptoms requiring prompt platelet reduction, anagrelide represents an important therapeutic option. It has a relatively high response rate, is active in patients in whom other plateletlowering agents may have failed, is not leukemogenic, has no effect on white blood cells and relatively minor effects on red blood cells, is orally active, can be administered for relatively 
a Some patients had more than one type of toxic manifestation.
long periods, and has a toxicity profile that is significantly different from other agents.
Conclusion
Based on the results of this open-label uncontrolled retrospective analysis, anagrelide effectively and rapidly reduces peripheral platelet counts in the majority of patients, with thrombocytosis accompanying CML refractory to HU. Treatment with anagrelide is well tolerated without undue toxicity. Reduction of significantly elevated platelet counts by anagrelide in patients with CML may prevent the thrombohemorrhagic complications that can occur in this disease. The role of anagrelide in the imatinib era remains to be determined. The occurrence of thrombohemorrhagic complications in CML is relatively rare, but its possibility should be remembered in those patients with increased platelet counts.
